XC001 – Entering PI/II


XC001 is a gene therapy for treatment of patients with refractory angina with no treatment options.  Patients who have exhausted pharmacologic options and are not eligible for PCI or coronary artery bypass grafts become sedentary because of their symptoms and this can exacerbate comorbidities causing rapid deterioration of their health status.  XC001 is designed to stimulate the formation of new coronary blood vessels to serve areas of the heart that are not receiving adequate blood supply.  This treatment strategy is based on both pre-clinical and clinical evidence and should enable the patients to become less limited in their daily activities because of debilitating chest pain.  XC001 has an open IND and is ready to start a Phase I/II trial.


XC002 – Discovery Stage


XC002 is the second XyloCor program and it is being developed for regeneration of cardiac tissue in patients who have poorly functioning hearts as a result of past heart attacks and resulting heart failure.  XC002 has transformed non-functioning cardiac cells into function cardiac cells in animal models.